Korean Society for
Clinical Laboratory ScienceKorean Journal of
CLINICAL LABORATORY SCIENCE

ORIGINAL ARTICLE

Evaluation of Commercial Complementary DNA Synthesis Kits for Detecting Human Papillomavirus

Kwangmin Yu¹, Sunyoung Park², Yunhee Chang¹, Dasom Hwang¹, Geehyuk Kim³, Jungho Kim⁴, Sunghyun Kim⁵, Eun-Joong Kim⁶, Dongsup Lee⁷¹Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju, Korea²Department of Mechanical Engineering, Yonsei University, Seoul, Korea³Ministry of Food and Drug Safety Pharmaceutical Safety Bureau, Osong Health Technology Administration Complex, Osong, Korea⁴Clinical Vaccine Research Section, International Tuberculosis Research Center, Seoul, Korea⁵Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Pusan, Korea⁶Department of Clinical Laboratory Science, Chungbuk Health and Science University, Cheongju, Korea⁷Department of Clinical Laboratory Science, Hyejeon College, Hongseong, Korea

인유두종바이러스 검출을 위한 상용화된 cDNA 합성 키트의 평가

유광민¹, 박선영², 장연희¹, 황다솜¹, 김지혁³, 김정호⁴, 김성현⁵, 김은중⁶, 이동섭⁷¹연세대학교 임상병리학과, ²연세대학교 기계공학과, ³식품의약품안전처 의약품안전국, ⁴국제결핵연구소 백신연구부, ⁵부산가톨릭대학교 임상병리학과,⁶충북보건과학대학교 임상병리과, ⁷혜전대학교 임상병리과

ARTICLE INFO

Received July 1, 2019
Revised 1st August 21, 2019
Revised 2nd August 25, 2019
Accepted August 25, 2019

Key words

Cervical cancer
Complementary DNA
Complementary DNA synthesis kit
Human papillomavirus
Real-time PCR

ABSTRACT

Cervical cancer is the fourth most common malignant neoplasm in women worldwide. Most cases of cervical cancer are caused by an infection by the human papillomavirus. Molecular diagnostic methods have emerged to detect the HPV for sensitivity, specificity, and objectivity. In particular, real-time PCR has been introduced to acquire a more sensitive target DNA or RNA. RNA extraction and complementary DNA synthesis are proceeded before performing real-time PCR targeting RNA. To identify an adequate and sensitive cDNA synthesis kit, this study evaluated the two commonly used kits for cDNA synthesis. The results show that the R² and efficiency (%) of the two cDNA synthesis kits were similar in the cervical cancer cell lines. On the other hand, the Takara kit compared to Invitrogen kit showed $P < 0.001$ in the 10² and 10³ SiHa cell count. The Takara kit compared to the Invitrogen kit showed $P < 0.001$ in the 10¹ and 10² HeLa cell count. Furthermore, 8, 4, 2, 1, and 0.5 ml of forty exfoliated cell samples were used to compare the cDNA synthesis kits. The Takara kit compared to the Invitrogen kit showed $P < 0.01$ in 8, 4, and 1 ml and $P < 0.05$ in 0.5 mL. The study was performed to identify the most appropriate cDNA synthesis kit and suggests that a cDNA synthesis kit could affect the real-time PCR results.

Copyright © 2019 The Korean Society for Clinical Laboratory Science. All rights reserved.

INTRODUCTION

Cervical cancer is the fourth common malignant neoplasm in women worldwide [1]. In accordance with

World Health Organization (WHO), cervical cancer occurred with approximately 530,000 new patients and 311,000 deaths per year globally [2]. Annually, approximately 3,500 patients are diagnosed and 960 patients die due to cervical cancer in Korea [3].

Since human papillomavirus (HPV) has been considered as the main cause of cervical cancer [4, 5]. HPV test is used to screen cervical cancer [6, 7]. HPV screening test consists

* Corresponding author: Dongsup Lee

Department of Clinical Laboratory Science, Hyejeon College, 25 Daehak-gil, Hongseong 32244, Korea

E-mail: eastern3547@naver.com

* ORCID: <https://orcid.org/0000-0003-4375-2731>

pISSN 1738-3544 eISSN 2288-1662

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

of cytological diagnostic methods and molecular diagnostic methods. In cytological diagnosis, Pap smear is a procedure to test for HPV screening in women using microscopy [8, 9]. A Pap smear is initiated with collecting cells from the cervix [10]. By screening HPV, a Pap smear allows one to prevent cervical cancer [11]. Detecting these precancerous cells early with a Pap smear is a step in stopping cervical cancer. However, the cytological method is limited by the long-term procedure and the interpretation - can be subjective depending on the person [12, 13]. Therefore, molecular diagnostic methods have emerged to detect HPV for sensitivity, specificity, and objectivity [14-16].

HPV screening test is done by molecular diagnostic technology such as PCR, real-time PCR, and NASBA method using HPV DNA or RNA [17-20]. Especially, real-time PCR is more sensitive and specific molecular diagnostic method to detect live HPV in patients compared to other methods [21-24]. Real-time PCR for HPV screening test is performed after RNA extraction, complementary DNA (cDNA) synthesis, and amplification of cDNA [25-27]. Real-time PCR gene expression can depend on efficiency (%) of complementary DNA synthesis even if total RNA is extracted efficiently [28].

In this study, we selected and compared two commercially available cDNA synthesis kits for the identification of the most useful kit in HPV screening test by cervical cancer cell lines and exfoliated cell samples. Reaction efficiency (%), coefficient of variation and cycle threshold (Ct) value analysis was performed.

MATERIALS AND METHODS

1. Cell line culture and clinical samples

Cervical cancer cell lines (HeLa and SiHa) were purchased from American Type Culture Collection ATCC (Manassas, USA) and Korean Cell Line Bank (Seoul, Korea). SiHa and HeLa cell line were cultured in Dulbecco's modified Eagle's Medium (DMEM; Gibco, Carlsbad, USA), with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) and 1% streptomycin-penicillin (Gibco, Carlsbad,

CA, USA). All cell lines were incubated at 37°C in humidified 5% CO₂ atmosphere. Forty exfoliated cell samples were collected from cervical cancer patients and healthy subjects at Wonju Severance Christian Hospital, Wonju, Korea, from January 2010 to December 2014. All subjects provided clinical information and this study was approved by the Institutional Ethics Committee of Yonsei University Wonju College of Medicine (Approval No. YWMR-12-4-010).

2. Total RNA extraction

To extract RNA in cervical cancer cell lines, 1 mL of Isol-RNA Lysis Reagent (5Prime, Hamburg, Germany) was added to the cell pellet. Cells were lysed by vortexing or repeated pipetting and left to stand at room temperature for 5 min. Subsequently, 200 µL of chloroform was added and the mixture was shaken vigorously and incubated at room temperature for 3 min before centrifugation at 12,000 ×g for 15 min. The resulting aqueous layer was transferred to a new tube and an equal volume of isopropanol was added and mixed by inverting the tube. After incubation for 10 min at 25°C and centrifugation at 12,000 ×g for 10 min, 1 mL of 75% ethanol was added to the supernatant and mixed by inverting the tube. Finally, the mixture was centrifuged at 7,500 ×g for 5 min and the supernatant was removed. The RNA pellet was dried and eluted in 25 µL of diethylpyrocarbonate-treated water (Intron Biotechnology, Seoul, Korea). The purity and concentration of total RNA were determined by measuring the absorbance at 260 nm and 280 nm using an Infinite 200 spectrophotometer (Tecan, Vienna, Austria). All steps in the preparation and handling of total RNA were conducted in a laminar flow hood under RNase-free conditions. The isolated total RNA was stored at -70°C until use.

3. cDNA synthesis

By using MMiV Reverse Transcriptase kits (Invitrogen, Carlsbad, CA, USA) and random hexamers (Invitrogen, Carlsbad, CA, USA), complementary DNA (cDNA) was synthesized according to the manufacturer's recom-

mendation. In short, 5 μ L of total RNA was added to a mixture containing 1 μ L of 10 mM dNTP mix at neutral pH, 1 μ L of 0.25 μ g/ μ L random hexamers, and 6 μ L of DEPC-treated water. The PCR mixtures were incubated at 65°C for 5 min and chilled on ice. After adding a mixture of 4 μ L of First-strand Buffer (5 $\times$), 2 μ L of 0.1 M dithiothreitol (DTT), and 1 μ L of MMLV reverse transcriptase (at room temperature), cDNA synthesis was performed at 25°C for 10 min, 37°C for 50 min and 70°C for 15 min. The cDNA was stored at -70°C until used. And By using PrimeScript RT Master Mix kits (Takara, Japan), cDNA was synthesized according to the manufacturer's recommendation. In short, 5 μ L of total RNA was added to a mixture containing 5 μ L of 5 $\times$ Master mix and 11 μ L of DEPC-treated water. cDNA synthesis was performed at 37°C for 15 min, and 85°C for 5 s.

4. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for detecting HPV types

The assay consists of three different sets of HR-HPV and detects 16 HR-HPV genotypes in three tubes (group I: HPV 16 [FAM], 33, 58 [HEX], and 31, 35 [Cy5]; group II: HPV 18 [FAM], 39, 68 [HEX], and 45 ~51 [Cy5]; group III: HPV 53, 56, 66 [FAM], 59, 69 [HEX], and 52 [Cy5]), by incorporating specific TaqMan probes labeled with different fluorophores. RT-qPCR were performed using 10 μ L of 2 $\times$ Thunderbird probe qPCR mix (Toyobo, Osaka, Japan), 5 μ L of primer and TaqMan probe mixture, 2 μ L of template cDNA, and distilled water to a final volume of 20 μ L per sample. No-template controls as negative controls were included in each run and contained sterile distilled water rather than template DNA. The PCR cycle was run as follows: 95°C for 3 min, followed by 40 cycles of 95°C for 3 s, and 55°C for 30 s. mRNA levels were quantified by determining the cycle threshold (CT), which is defined as the number of PCR cycles required for fluorescence to exceed a value significantly higher than that of the background fluorescence. For internal control, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used.

5. Data calculation and statistical analysis

The qPCR R^2 and efficiency (%) was calculated by qPCR Efficiency Calculator Program (ThermoFisher Scientific, CA, USA). Statistical analysis was conducted using GraphPad Prism software (Version 5.02, La Jolla, CA, USA). Two way-ANOVA tests were used to determine the statistical significance in cDNA synthesis kits. For all tests, $P < 0.05$ was considered statistically significant. The differences were considered statistically significant when * $P < 0.05$, ** $P < 0.01$, or *** $P < 0.001$.

RESULTS

1. Reaction efficiency (%), R^2 and limit of detection in SiHa cell line

To compare the cDNA synthesis efficiency (%) of two commercial kits, SiHa cell line was diluted from 10^6 to 10^0 and then SiHa cell line cDNA was synthesized by two RT-PCR kits and used for amplification of real-time PCR targeting HPV 16 and GAPDH. R^2 of the two cDNA synthesis kits was 0.99 and 0.99, respectively (Table 1). And efficiency (%) of the two cDNA synthesis kits was 107.71 and 103.98 respectively (Table 1). And limit of detection was 10^1 and 10^2 cells in Takara and Invitrogen kits (Table 1). Takara kit compared to Invitrogen kit showed $P < 0.001$ in 10^2 and 10^3 cell count (Figure 1). 95% confidence interval were “-8.004 to 0.004441” “-12.00 to -3.996” “-14.80 to -6.796” “-5.404 to 2.604” “-5.104 to 2.904” “-5.104 to 2.904” from 10^1 to 10^6 . GAPDH Ct value range was between 25 ~30.

Table 1. R^2 , efficiency (%) and limit of detection in SiHa cell line according to cDNA synthesis kits

	Invitrogen	Takara
R^2	0.99	0.99
Efficiency (%)	107.71	103.98
Limit of detection (Cells)	10^2	10^1

Figure 1. Ct values comparison between Invitrogen and Takara kit in SiHa cell line. Takara kit compared to Invitrogen kit showed $P<0.001$ in 10^3 and 10^2 cell count (bar represents mean and standard deviation).

Figure 2. Ct values comparison between Invitrogen and Takara kit in HeLa cell line. Takara kit compared to Invitrogen kit showed $P<0.001$ in 10^2 and 10^1 cell count (bar represents mean and standard deviation).

Table 2. R^2 , efficiency (%) and limit of detection in HeLa cell line according to cDNA synthesis kits

	Invitrogen	Takara
R^2	0.95	0.99
Efficiency (%)	96.84	107.23
Limit of detection (Cells)	10^3	10

2. Reaction efficiency (%), R^2 and limit of detection in HeLa cell line

To compare the cDNA synthesis efficiency (%) of two commercial kits, HeLa cell line was serially diluted 10-fold from 10^6 to 10^0 . Then HeLa cell line cDNA was synthesized by two RT-PCR kits and used for amplification of real-time PCR targeting GAPDH and HPV 18. R^2 of the two cDNA synthesis kits was 0.95 and 0.99, respectively (Table 2). And efficiency (%) of the two cDNA synthesis kits was 96.84 and 107.23 respectively (Table 2). And limit of detection was 10 and 10^3 cells in Takara and Invitrogen kits (Table 2). Takara kit compared to Invitrogen kit showed $P<0.001$ in 10^1 and 10^2 cell count (Figure 2). 95% confidence interval were “-7.790 to -2.210” “-9.790 to -4.210” “-3.390 to 2.190” “-4.890 to 0.6903” “-3.990 to 1.590” “-2.890 to 2.690” from 101 to 106. GAPDH Ct value range was between 25~30.

3. Ct value analysis in exfoliated cell samples

8, 4, 2 and 1 ml of forty exfoliated cell samples were

Figure 3. Ct values comparison between Invitrogen and Takara kit in clinical samples. Takara kit compared to Invitrogen kit showed $P<0.01$ in 8, 4, 1 mL and $P<0.05$ in 0.5 mL (bar represents mean and standard deviation).

used to compare the cDNA synthesis efficiency (%) of two commercial kits. Takara kit compared to Invitrogen kit showed $P<0.05$ in 0.5 ml and $P<0.01$ in 8, 4, 1 mL (Figure 3) representing that Takara kit has capacity to detect more HPV nucleic acid. 95% confidence interval were “-1.902 to -0.09788” “-2.002 to -0.1979” “-1.402 to 0.4021” “-2.102 to -0.2979” “-2.102 to -0.2979” according to 1,2,4 and 8 ml of clinical samples. GAPDH Ct value range was between 25~30.

DISCUSSION

The HPV-induced carcinogenesis has the pattern that expression of the E6 and E7 gene of HPV is maintained,

while other viral DNA is deleted or disturbed [36]. Detection of HPV oncogene activity through the detection of mRNA transcripts may therefore be a better indicator of HPV infection associated with increased risk of progression to neoplasia than detection of HPV DNA [37].

Recently, real-time PCR has become the most powerful detection system for nucleic acids of bacteria, virus, and human and is used to diagnose cervical cancer in several hospital especially [29-31]. Diagnostic lab system for introducing real-time PCR are now confronted with defining the most adequate kit for their real-time PCR applications. Concerns have been raised that real-time PCR components and condition can affect on sensitivity and specificity of results for real-time PCR platform [32]. Real-time PCR performance needs to be verified, for many parameters can influence the results of real-time PCR amplification. Therefore, it is essential that laboratories employing real-time PCR platform apply strict laboratory quality control standards.

Two-step real-time PCR has flexibility using random primer and oligo dT and is used for the amplification of different targets in small amount of same sample [33]. In the study, we selected and evaluated the two-step real-time PCR kits for HPV is divided into various low-risk and high-risk groups which exist in small amount of clinical samples.

Especially, the reverse transcription reaction before acquiring real-time PCR results is a key step in real-time PCR. RT enzymes, which are the most important for real-time RT-PCR assay, are critical for synthesizing cDNA resulting in real-time PCR data analysis [34]. For many quantitative results, the MMLV (Moloney Murine Leukemia Virus) reverse transcriptase is used. The enzyme of capacity is greater than any other commercial reverse transcriptase [35]. In the study, two commercial kits used RT originated from MMLV using cervical cancer cell lines and clinical samples.

The purpose of the study was for evaluating the efficiency (%) of cDNA synthesis kits. For that study, HPV was selected to generate HPV RNA transcript. We selected two different commercial cDNA synthesis kits for

detecting HPV and evaluated the results using efficiency and R^2 as shown in a paper [28]. Results showed that efficiency (%) was between 90%~110%, R^2 was above 0.96. Results demonstrated that there was no difference in reaction efficiency (%) and R^2 values between two methods in cervical cancer cell line which has HPV 16 and 18 for causing cervical cancer. Cervical cancer cell lines except other cell lines were used to define the diagnostic method for cervical cancer. However, considering limit of detection, Takara kit compared to Invitrogen kit showed statistically significant that Takara kit is more sensitive method for detecting HPV load in same quantity. It is assumed that Takara kit has more primers binding to RNA such as oligo dT and random hexamer with RNase inhibitor. Actually, random primer can be used for shortness of gene sequence or sequence region which has difficulty to be elongated by binding to mRNA, rRNA and tRNA. Oligo dT has advantage that full-length cDNA can be synthesized and small amount of target mRNA can be amplified by several elongation steps by binding to same mRNA molecule. In conclusion, these results suggest quality of real-time PCR data analysis and experiment can be elevated according to cDNA synthesis kit strongly. Further studies need to be performed on a variety of clinical samples, more cDNA synthesis kits and various cancers.

요 약

자궁경부암은 전 세계적으로 네번째를 차지하는 여성암이다. 자궁경부암의 대부분 원인은 인유두종 바이러스의 감염이다. 인유두종 바이러스를 검출하기 위해 다양한 분자진단학적 방법들이 고안되었다. 분자진단학적 방법 중의 real-time PCR은 목표 DNA 또는 RNA의 정량과 민감도 향상을 목표로 도입되었다. 특히, real-time PCR 과정은 수행 전에 RNA 추출 및 상보적인 DNA 합성 과정이 필요하다. 따라서 본 연구에서는 민감하고 적합한 상보적인 DNA 합성 키트를 알아보기 위해서 상보적인 DNA 합성에 이용되는 두 개의 상용화된 키트를 평가하였다. 자궁경부암 세포주에서 두 개의 상보적인 DNA 합성 키트의 R^2 과 효율성을 비교한 결과 차이가 없었다. 그러나 Invitrogen 키트보다 Takara 키트가 10^2 및 10^3 SiHa 세포주에서 $P<0.001$ 를

나타내었고 10^1 및 10^2 HeLa 세포주에서도 $P < 0.001$ 를 나타내었다. 이를 통해 Takara 키트가 Invitrogen 키트보다 민감도가 높음을 알 수 있었다. 또한 40개의 탈락세포검체의 8, 4, 2, 1 mL 을 이용하여 상보적인 DNA 합성 키트를 비교한 결과 Invitrogen 키트보다 Takara 키트가 8, 4, 1 mL에서 $P < 0.01$ 및 0.5 mL에서 $P < 0.05$ 을 나타내어 임상 검체를 이용하였을 때에도 Takara 키트가 Invitrogen 키트보다 민감도가 높음을 알 수 있었다. 본 연구는 적합한 상보적인 DNA 합성 키트를 확인하기 위해 수행되었으며, 상보적인 DNA 합성 키트가 real-time PCR 결과 다양성에 영향을 미친다는 것을 시사하였다.

Acknowledgements: This research was supported by Hyejeon College grant.

Conflict of interest: None

Author's information (Position): Yu K¹, Graduate student; Park S², Researcher; Chang Y¹, Graduate student; Hwang D¹, Graduate student; Kim G³, Researcher; Kim J⁴, Researcher; Kim S⁵, Professor; Kim E⁶, Professor; Lee D⁷, Professor.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68:394-424.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol*. 1999;189:12-19.
3. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. *Cancer Res Treat*. 2018;50:303-316.
4. Eileen M. Human papillomavirus and cervical cancer. *Clin Microbiol Rev*. 2003;16:1-17.
5. Maucourt-Boulch D, Franceschi S, Plummer M. International correlation between human papillomavirus prevalence and cervical cancer incidence. *Cancer Epidemiol Biomarkers Prev*. 2008;17:717-720. <https://doi.org/10.1158/1055-9965.EPI-07-2691>.
6. Wentzensen N, Arbyn M. HPV-based cervical cancer screening- facts, fiction, and misperceptions. *Prev Med*. 2017;98: 33-35. <https://doi.org/10.1016/j.ypmed.2016.12.040>.
7. Park SM, Lee SK, Kim YS. Inhibition of cervical cancer cell growth by gene silencing of HPV16 E6 induced by short-interfering RNA. *Korean J Clin Lab Sci*. 2011;43:89-97.
8. Baptista AD, Simão CX, Santos VCGD, Melgaço JG, Cavalcanti SMB, Fonseca SC, et al. Knowledge of human papillomavirus and Pap test among Brazilian university students. *Rev Assoc Med Bras*. 2019;65:625-632. <https://doi.org/10.1590/1806-9282.65.5.625>.
9. Watson M, Benard V, King J, Crawford A, Saraiya M. National assessment of HPV and Pap tests: Changes in cervical cancer screening, National Health Interview Survey. *Prev Med*. 2017;100:243-247. <https://doi.org/10.1016/j.ypmed.2017.05.004>.
10. Al-Nourhji O, Dermawan JK, Booth CN, Underwood D, Abdul-Karim FW. Role of ThinPrep liquid-based cytology in evaluation of the endocervical canal in patients with abnormal cervical screening. *J Am Soc Cytopathol*. 2019;8:278-283. <https://doi.org/10.1016/j.jasc.2019.05.001>.
11. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. *Cancer Cytopathol*. 2015;123:271-281. <https://doi.org/10.1002/cncy.21521>.
12. Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. *Cochrane Database Syst Rev*. 2017;10:8:CD008587. <https://doi.org/10.1002/14651858.CD008587.pub2>.
13. El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. *J Clin Virol*. 2016;76(Suppl 1):S62-S68. <https://doi.org/10.1016/j.jcv.2015.11.020>.
14. Pruski D, Millert-Kalinska S, Lewek A, Kedzia W. Sensitivity and specificity of HR HPV E6/E7 mRNA test in detecting cervical squamous intraepithelial lesion and cervical cancer. *Ginekol Pol*. 2019;90:66-71. <https://doi.org/10.5603/GP.2019.0011>.
15. Park SY, Yoon HS, Bang HE, Kim Y, Cho SK, Ahn SW, et al. Analytical performance of sensitivity and specificity for rapid multiplex high risk human papillomavirus detection kit: HPV ViroCheck. *Korean J Clin Lab Sci*. 2017;49:446-454.
16. Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. *J Clin Virol*. 2016;76(Suppl 1):3-13. <https://doi.org/10.1016/j.jcv.2015.10.023>.
17. Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, Bogers JJ. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. *J Cell Mol Med*. 2007;11:881-891.
18. Kim GH, Park SY, Wang HY, Kim SH, Park SJ, Yu KM, et al. Distribution of oncogenic human papillomavirus genotypes at high grade cervical lesions above CIN 2 grade with histological diagnosis. *Biomed Sci Lett*. 2016;22:98-106.
19. Roberts CC, Swoyer R, Bryan JT, Taddeo FJ. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection. *J Clin Microbiol*. 2011;49:1899-1906. <https://doi.org/10.1128/JCM.00235-10>.
20. Pasquier C, Sauné K, Raymond S, Boisseau J, Courtade M, Izopet J. Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus. *Diagn Microbiol Infect Dis*. 2017;87:25-27. <https://doi.org/10.1016/j.diagmicrobio.2016.08.022>.
21. Pan C, Zhou J, Lyu J, Ren X. Development and validation of a multiplex reverse transcript real-time PCR for E6/E7 mRNA detection of high-risk human papillomavirus. *J Med Microbiol*.

- 2018;67:1509-1514. <https://doi.org/10.1099/jmm.0.000824>.
22. Şahiner F, Kubar A, Yapar M, Şener K, Dede M, Gümrall R. Detection of major HPVs by a new multiplex real-time PCR assay using type-specific primers. *J Microbiol Methods*. 2014;97:44-50. <https://doi.org/10.1016/j.mimet.2013.12.012>.
23. Yang H, Li LJ, Xie LX, Luo ZY, Lu M, Lin M, et al. Clinical validation of a novel real-time human papillomavirus assay for simultaneous detection of 14 high-risk HPV type and genotyping HPV type 16 and 18 in China. *Arch Virol*. 2016;161:449-454. <https://doi.org/10.1007/s00705-015-2673-y>.
24. Micallessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE. High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. *Clin Chem Lab Med*. 2011;50:655-661. <https://doi.org/10.1515/cclm.2011.835>.
25. Harvey RJ, Darlison MG. Random-primed cDNA synthesis facilitates the isolation of multiple 5'-cDNA ends by RACE. *Nucleic Acids Res*. 1991;19:4002. <https://doi.org/10.1093/nar/19.14.4002>.
26. Michaelidou K, Tzovaras A, Missitzis I, Ardavanis A, Scorilas A. The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. *Int J Oncol*. 2013;42:1770-1777. <https://doi.org/10.3892/ijo.2013.1860>.
27. Yuan JS, Reed A, Chen F, Stewart CN Jr. Statistical analysis of real-time PCR data. *BMC Bioinformatics*. 2006;7:85. <https://doi.org/10.1186/1471-2105-7-85>.
28. Picard-Meyer E, Peytavin de Garam C, Schereffer JL, Marchal C, Robardet E, Cliquet F. Cross-platform evaluation of commercial real-time SYBR green RT-PCR kits for sensitive and rapid detection of European bat Lyssavirus type 1. *Biomed Res Int*. 2015;2015:839518. <https://doi.org/10.1155/2015/839518>.
29. Kim GH, Cho HM, Lee DS, Park SY, Lee JY, Wang HY, et al. Comparison of FFPE histological versus LBP cytological samples for HPV detection and typing in cervical cancer. *Exp Mol Pathol*. 2017;102:321-326. <https://doi.org/10.1016/j.yexmp.2017.02.015>.
30. Wang HY, Lee DS, Park SY, Kim GH, Kim SH, Han L, et al. Diagnostic performance of HPV E6/E7 mRNA and HPV DNA assays for the detection and screening of oncogenic human papillomavirus infection among woman with cervical lesions in China. *Asian Pac J Cancer Prev*. 2015;16:7633-7640.
31. Wang HY, Park SY, Lee DS, Kim SH, Kim GH, Park KH, et al. Prevalence of type-specific oncogenic human papillomavirus infection assessed by HPV E6/E7 mRNA among women with high-grade cervical lesions. *Int J Infect Dis*. 2015;37:135-142. <https://doi.org/10.1016/j.ijid.2015.06.018>.
32. Buzard GS, Baker D, Wolcott MJ, Norwood DA, Dauphin LA. Multi-platform comparison of ten commercial master mixes for probe-based real-time polymerase chain reaction detection of bioterrorism threat agents for surge preparedness. *Forensic Sci Int*. 2012;223:292-297. <https://doi.org/10.1016/j.forsciint.2012.10.003>.
33. Wacker MJ, Godard MP. Analysis of one-step and two-step real-time RT-PCR using SuperScript III. *J Biomol Tech*. 2005;16:266-271.
34. Jacob F, Guertler R, Naim S, Nixdorf S, Fedier A, Hacker NF, et al. Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines. *PLoS One*. 2013;8:E59180. <https://doi.org/10.1371/journal.pone.0059180>.
35. Pfaffl M. Quantification strategies in real-time PCR. In: Bustin S, editor. *A-Z of Quantitative PCR*. chapter 3. La Jolla, CA, USA: International University Line; 2004; p. 87-112.
36. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. *J Virol*. 1987;61:962-971.
37. Lie AK1, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, Onsrud M, Thoresen S. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. *Gynecol Oncol*. 2005;97:908-915. <https://doi.org/10.1016/j.ygyno.2005.02.026>.